er-086526 and Renal-Insufficiency--Chronic

Systemic treatments for advanced soft tissue sarcoma are limited. Eribulin showed activity in metastatic soft tissue sarcoma, particularly liposarcomas. Data from six patients with advanced liposarcoma that received eribulin as third- or fourth-line therapy are presented herein. Eribulin treatment was well tolerated; no grade 3-4 toxicity or therapy delay was observed. Two patients had a partial response; four had a prolonged stable disease. The first case, with pre-existing chronic renal dysfunction, achieved a 6-month stable disease with dose-reduced eribulin. The second case became resectable after eribulin treatment, with a 6-month complete surgical remission. The third case obtained a 7-month stable disease with eribulin and stereotactic body radiotherapy. The last three cases were ≥65 years old, and two of them had objective response with eribulin.

Topics: Aged; Antineoplastic Agents; Biomarkers; Female; Furans; Humans; Ketones; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Renal Insufficiency, Chronic; Retreatment; Tomography, X-Ray Computed; Treatment Outcome